Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab in mild to moderate SLE
NCT06881290Phase 1Recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- May 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vunakizumab in systemic lupus erythematosus (SLE), sponsored by Chinese SLE Treatment And Research Group. Primary endpoint: BICLA Response at 24 weeks. Started May 2025; status: recruiting.
02
Drugs
vunakizumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06881290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881290.